Mindpeak and Revolune Announce Commercial Co-Selling Partnership to Deliver End-to-End Spatial Biology Solutions

September 21, 2026

Partnership combines Mindpeak’s PhenoScout™ AI image analysis with Revolune’s multiplex IF kits to streamline the path from tissue staining to spatial discovery.

Hamburg, Germany - September 21, 2026 - Mindpeak, a leader in clinical-grade artificial intelligence for digital pathology, and Revolune, an innovator in accessible multiplex immunofluorescence (mIF) technologies, today announced a commercial co-selling partnership to offer an integrated workflow combining multiplex tissue staining with AI-powered image analysis.

Under the agreement, Mindpeak’s PhenoScout™ AI platform will be offered directly alongside Revolune’s multiplex reagent kits, providing researchers with an integrated path from tissue staining to spatial insights.

From Multiplex Staining to Spatial Insights

Multiplex immunofluorescence is transforming the way researchers characterize the tumor immune microenvironment, evaluate antibody-drug conjugates (ADCs), and identify translational biomarkers. As spatial biology continues to advance, researchers need workflows that make it easier to generate, interpret, and act on multiplex data with confidence.

The Revolune–Mindpeak partnership brings these capabilities together in one streamlined workflow:

Flexible Multiplex Staining:
Revolune enables laboratories to move quickly from validated primary antibodies to ready-to-use 4- to 7-plex kits without complex assay development.

Turnkey AI Analysis:
PhenoScout AI by Mindpeak automates cell detection, tumor/stroma segmentation, phenotyping, and spatial neighborhood metrics in minutes, eliminating the need for bioinformatics pipelines or manual thresholding.

“Multiplex immunofluorescence shouldn’t become complicated at the analysis step,” said Adrian Arechiga, CCO of Revolune. “Revolune removes the complexity of generating high-quality mIF data. By co-selling Mindpeak’s PhenoScout AI, we provide an integrated workflow that takes researchers from antibody staining to quantitative spatial data in minutes, enabling cohort-scale studies without bioinformatics backlogs.”

“Mindpeak was founded to bring precision, reproducibility, and automation to cellular pathology,” said Felix Faber, CEO of Mindpeak. “PhenoScout delivers turnkey spatial analysis out of the box using pre-trained foundation models. Partnering with Revolune creates an ideal synergy, pairing validated staining chemistry directly with fast, reproducible AI analysis.”

Evaluate the Integrated Workflow

To mark the launch, researchers purchasing qualifying Revolune multiplex IF kits will receive promotional PhenoScout AI analysis credits.

The introductory offer gives translational research teams and CROs the opportunity to evaluate the complete stain-to-insight workflow on their own tissue samples before transitioning to flexible annual subscription packages.

Explore the integrated workflow

PhenoScout AI is developed by Mindpeak and available through Revolune. For Research Use Only (RUO).

‍

About Revolune

Revolune is a life science company dedicated to making multiplex immunofluorescence as accessible and practical as routine tissue analysis. Its reagent technologies help laboratories move rapidly from existing primary antibodies to ready-to-use multiplex kits, simplifying spatial biology workflows and enabling researchers to focus on biological questions rather than assay management.

‍

About Mindpeak

Mindpeak is a leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak’s AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images — ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications.

‍

Press Release

Related reading

We are excited to announce a global reseller agreement with Leica Biosystems, a Danaher company and global leader in digital pathology. This partnership marks an important step in expanding access to Mindpeak’s AI-powered pathology solutions worldwide.
Press Release
8 min read

Mindpeak Announces Global Reseller Agreement with Leica Biosystems

We are excited to announce a global reseller agreement with Leica Biosystems, a Danaher company and global leader in digital pathology. This partnership marks an important step in expanding access to Mindpeak’s AI-powered pathology solutions worldwide.

We are excited to announce a global reseller agreement with Leica Biosystems, a Danaher company and global leader in digital pathology. This partnership marks an important step in expanding access to Mindpeak’s AI-powered pathology solutions worldwide.

By integrating our AI applications into the Aperio HALO AP platform and Aperio AI Store, laboratories and biopharma teams can seamlessly bring advanced biomarker and tissue analysis into their daily workflows -supporting greater efficiency, reproducibility, and scalability.

Together, we aim to accelerate biomarker discovery and enable smarter decisions across the drug development lifecycle.

Read the full Press Release here: https://www.einpresswire.com/article/900262524/mindpeak-announces-global-reseller-agreement-with-leica-biosystems-to-expand-access-to-ai-pathology-solutions

Press Release
8 min read

Mindpeak Secures First Patent for Advanced AI in Digital Pathology

Mindpeak has been granted its first patent, marking an important milestone in the company’s mission to advance AI-powered pathology and precision diagnostics.

The patent protects a novel method for training artificial intelligence systems to accurately identify and classify different cell types in tissue samples. This technology addresses a critical requirement for reliable cancer diagnostics and reinforces the role of AI as a dependable decision-support tool for pathologists.

The patent has been issued across 18 European Union member states and validated in the United Kingdom, highlighting the originality, robustness, and clinical relevance of Mindpeak’s approach to digital pathology.

This achievement reflects the dedication and expertise of Mindpeak’s research, development, and engineering teams, whose work continues to advance the capabilities of medical AI.

For further information, please refer to the full press release:
https://www.globenewswire.com/news-release/2025/12/10/3202933/0/en/Mindpeak-Secures-First-Patent-for-Advanced-AI-Method-in-Digital-Pathology.html

‍

Press Release
8 min read

Accelerating AI Adoption in Pathology: Mindpeak x PathGroup

The role of AI in pathology isn’t just evolving – it’s accelerating. It’s helping pathologists turn complex data into faster, more consistent answers for patients. At Mindpeak, we’re proud to be part of that change. Today, we’re taking another big step forward through a new collaboration with PathGroup – one of the leading providers of anatomic, clinical, molecular and digital pathology services in the U.S.

This partnership goes beyond collaboration; it marks a powerful step toward bringing AI into everyday diagnostics. By combining Mindpeak’s proprietary image analysis technology with PathGroup’s extensive, pathologist-led network, we’re laying the groundwork for a new era of precision and efficiency in pathology.

Together, we’ll support pathologists integrate AI seamlessly into their workflows – enhancing speed, consistency and equity in diagnostics. The result: faster, more reliable insights for patients and more time for pathologists to focus on what matters most – patient care.

At Mindpeak, we believe the future of pathology is AI-augmented, not AI-replaced. Through partnerships like this, that future is becoming reality – one slide at a time.

‍

‍

Read more here

Ready to advance your diagnostics

Connect with our team to explore how precision pathology works in your setting